Oncology News and Research RSS Feed - Oncology News and Research Twitter

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.
Vice President Biden to host Cancer Moonshot Summit in Washington, D.C.

Vice President Biden to host Cancer Moonshot Summit in Washington, D.C.

Vice President Biden and Dr. Jill Biden will host a Cancer Moonshot Summit in Washington, D.C. at the White House. Cheryl Willman, MD, Director and CEO of The University of New Mexico Comprehensive Cancer Center, will attend. [More]
Oncogene signatures could help design new drug treatments for breast cancer

Oncogene signatures could help design new drug treatments for breast cancer

Drug treatments for breast cancer patients might soon be designed based on the unique genetic autograph of their tumor. [More]
Siemens Healthineers' new CT and MRI technologies to aid research across various common clinical pathways

Siemens Healthineers' new CT and MRI technologies to aid research across various common clinical pathways

The Transforming Outcomes and Health Economics Through Imaging (TOHETI) programme is looking to change the way medical imaging works by undertaking a range of pioneering research. [More]
Researchers identify new potential target for pancreatic cancer treatment

Researchers identify new potential target for pancreatic cancer treatment

Using an innovative approach to identify a cancer's genetic vulnerabilities by more swiftly analyzing human tumors transplanted into mice, researchers have identified a new potential target for pancreatic cancer treatment, published online in Cell Reports. [More]
Mice study shows influence of dad's obesity on daughter’s body weight and breast cancer risk

Mice study shows influence of dad's obesity on daughter’s body weight and breast cancer risk

Obese male mice and normal weight female mice produce female pups that are overweight at birth through childhood, and have delayed development of their breast tissue as well as increased rates of breast cancer. [More]
Taking ipilimumab, nivolumab drugs may increase risk of developing rheumatologic diseases

Taking ipilimumab, nivolumab drugs may increase risk of developing rheumatologic diseases

Case reports on 13 cancer patients suggest that a small number of cancer patients taking the immunotherapy drugs ipilimumab and nivolumab may be at some higher-than-normal risk of developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a preliminary study by Johns Hopkins Medicine researchers. [More]
Pre-operative MRI for breast cancer patients may need to be done in a different position

Pre-operative MRI for breast cancer patients may need to be done in a different position

The difference in how a woman is positioned during MRI prior to breast conserving surgery and how she is positioned during the surgery distorts and displaces tumors while the surgery is being performed, report researchers. [More]
Pretreatment smoking linked to poor prognosis in AI-treated patients

Pretreatment smoking linked to poor prognosis in AI-treated patients

Among older aromatase inhibitor (AI)-treated patients with breast cancer, current smokers at treatment initiation have an increased risk of breast cancer events and distant metastases, say Swedish researchers. [More]
HCC predictors identified for chronic HBV patients with newly diagnosed cirrhosis

HCC predictors identified for chronic HBV patients with newly diagnosed cirrhosis

In patients with chronic hepatitis B virus infection who have been newly diagnosed with cirrhosis, the risk of hepatocellular carcinoma development can be ascertained using several clinical and molecular factors, study findings indicate. [More]
Novel combination therapy slows cancer growth in patients with advanced solid tumors

Novel combination therapy slows cancer growth in patients with advanced solid tumors

A phase 1 clinical trial testing a novel combination therapy developed by scientists at VCU Massey Cancer Center slowed the growth of cancer in the majority of trial participants, which were patients with advanced solid tumors. [More]
Salvage inotuzumab ozogamicin improves ALL outcomes

Salvage inotuzumab ozogamicin improves ALL outcomes

Compared with standard chemotherapy, treatment with inotuzumab ozogamicin increases the rate of complete remission and allows a higher proportion of patients with relapsed or refractory acute lymphoblastic leukaemia to subsequently receive stem-cell transplantation, research suggests. [More]
Moffitt researchers develop mathematical model to show differences in subpopulations of tumors

Moffitt researchers develop mathematical model to show differences in subpopulations of tumors

Tumors are composed of many subpopulations of cells. A general consensus among scientists is that these subpopulations are due to random mutations. However, Moffitt Cancer Center researchers found that these assumptions may be incorrect. [More]
Shorter course of prostate cancer radiotherapy could save NHS millions of pounds

Shorter course of prostate cancer radiotherapy could save NHS millions of pounds

A shorter course of prostate cancer radiotherapy, involving fewer hospital visits and higher individual doses of radiotherapy, is as effective as the current standard treatment for both survival and quality of life, a major new study reports. [More]
Telephone counseling can help make cancer genetic services more accessible to rural women

Telephone counseling can help make cancer genetic services more accessible to rural women

Ever since Angelina Jolie used cancer genetic counseling and testing to learn about her risk for hereditary breast and ovarian cancer, many other women have chosen to do the same. [More]
Cytoreductive nephrectomy can extend survival of metastatic kidney cancer patients

Cytoreductive nephrectomy can extend survival of metastatic kidney cancer patients

Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only about three in ten such patients undergo the procedure, according to a new study by researchers at Dana-Farber Cancer Institute and Brigham and Women's Hospital. [More]
VentureMed Group receives FDA 510(k) clearance for FLEX Scoring Catheter

VentureMed Group receives FDA 510(k) clearance for FLEX Scoring Catheter

VentureMed Group, Ltd., a medical device company based in northwest Ohio, has received 510(k) clearance from the U.S. Food and Drug Administration for the commercial distribution of a new surgical device for treating peripheral artery disease (PAD). [More]
Cabozantinib extends advanced RCC overall survival

Cabozantinib extends advanced RCC overall survival

Patients with advanced or metastatic renal cell carcinoma derive a significant overall survival benefit from second-line treatment with the multi-tyrosine kinase inhibitor cabozantinib relative to everolimus. [More]
ERCC2 validated as chemotherapy response biomarker in bladder cancer

ERCC2 validated as chemotherapy response biomarker in bladder cancer

Somatic mutations in the helicase-encoding ERCC2 gene are associated with response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive urothelial bladder carcinoma. [More]
New collaborative research program connects canine and human cancers

New collaborative research program connects canine and human cancers

A new collaborative research program pairs oncologists who treat childhood and adult sarcomas with veterinarians who manage the same cancers in canine patients. [More]
New research paves way for potential notch-based anticancer therapeutics

New research paves way for potential notch-based anticancer therapeutics

A recent study led by scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, in collaboration with the Univerity of Maryland School of Pharmacy and StemSynergy Therapeutics, Inc., has identified a small-molecule inhibitor of the Notch pathway, paving the way for a potential new class of personalized cancer medicines. [More]
Advertisement